Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.
Authors
Bielack, SSmeland, S
Whelan, J
Marina, N
Jovic, G
Hook, J
Krailo, M
Gebhardt, M
Pápai, Z
Meyer, J
Nadel, H
Randall, R
Deffenbaugh, C
Nagarajan, R
Brennan, Bernadette M
Letson, G
Teot, L
Goorin, A
Baumhoer, D
Kager, L
Werner, M
Lau, C
Sundby Hall, K
Gelderblom, H
Meyers, P
Gorlick, R
Windhager, R
Helmke, K
Eriksson, M
Hoogerbrugge, P
Schomberg, P
Tunn, P
Kühne, T
Jürgens, H
van den Berg, H
Böhling, T
Picton, S
Renard, M
Reichardt, P
Gerss, J
Butterfass-Bahloul, T
Morris, C
Hogendoorn, P
Seddon, B
Calaminus, G
Michelagnoli, M
Dhooge, C
Sydes, M
Bernstein, M
Affiliation
Klinikum Stuttgart-Olgahospital, StuttgartIssue Date
2015-06-01
Metadata
Show full item recordAbstract
EURAMOS-1, an international randomized controlled trial, investigated maintenance therapy with pegylated interferon alfa-2b (IFN-α-2b) in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy.Citation
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. 2015: J Clin OncolJournal
Journal of Clinical OncologyDOI
10.1200/JCO.2014.60.0734PubMed ID
26033801Type
ArticleLanguage
enISSN
1527-7755ae974a485f413a2113503eed53cd6c53
10.1200/JCO.2014.60.0734
Scopus Count
Collections
Related articles
- Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.
- Authors: Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, van den Berg H, Brennan B, Brichard B, Brown KLB, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R, Goorin A, Gorlick R, Grier HE, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PCW, Isakoff MS, Janeway KA, Jürgens H, Kager L, Kühne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MCG, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS
- Issue date: 2016 Oct
- Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
- Authors: Bajpai J, Chandrasekharan A, Talreja V, Simha V, Chandrakanth MV, Rekhi B, Khurana S, Khan A, Vora T, Ghosh J, Banavali SD, Gupta S
- Issue date: 2017 Nov
- EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.
- Authors: Whelan JS, Bielack SS, Marina N, Smeland S, Jovic G, Hook JM, Krailo M, Anninga J, Butterfass-Bahloul T, Böhling T, Calaminus G, Capra M, Deffenbaugh C, Dhooge C, Eriksson M, Flanagan AM, Gelderblom H, Goorin A, Gorlick R, Gosheger G, Grimer RJ, Hall KS, Helmke K, Hogendoorn PC, Jundt G, Kager L, Kuehne T, Lau CC, Letson GD, Meyer J, Meyers PA, Morris C, Mottl H, Nadel H, Nagarajan R, Randall RL, Schomberg P, Schwarz R, Teot LA, Sydes MR, Bernstein M, EURAMOS collaborators
- Issue date: 2015 Feb
- Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.
- Authors: Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, Memon MA, Weeden S, Uscinska BM, van Glabbeke M, Kirkpatrick A, Hauben EI, Craft AW, Taminiau AH, MRC BO06 and EORTC 80931 collaborators, European Osteosarcoma Intergroup
- Issue date: 2007 Jan 17
- Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma.
- Authors: Tsuda Y, Tsoi K, Parry MC, Stevenson JD, Fujiwara T, Sumathi V, Jeys LM
- Issue date: 2020 Jun